article thumbnail

David Liu receives Breakthrough Prize in Life Sciences

Broad Institute

Base editing, which Lius team developed in 2016, is a gene editing technique that directly converts an individual DNA base pair into a different base pair. In 2013, Broad founding director Eric S. Liu and other prize recipients were announced on April 5, 2025, at the 11th annual Breakthrough Prize ceremony in Los Angeles.

Science 139
article thumbnail

Perfume from Extinct Flowers, Thanks to Ancient DNA and Synthetic Biology

PLOS: DNA Science

“Meet Invisible Woods: a clean, refreshing scent revived from extinct flower DNA ,” beneath an image of “origin flower” Wendlandia angustifolia. • compare the DNA sequence to similar genes in other species. • tweak a lab-made copy of the DNA sequence using clues from other plant species.

DNA 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DNA Analysis Finds New Target for Diabetes Drugs

NIH Director's Blog: Drug Development

Credit: Jane Ades, National Human Genome Research Institute, NIH Type 2 diabetes (T2D) tends to run in families, and over the last five years the application of genomic technologies has led to discovery of more than 60 specific DNA variants that contribute to risk. 2013 Aug;12(8):581-94. [3] 2013 Oct 1;123(10):4513-24. [6]

DNA 52
article thumbnail

Arylidene and amino spacer?linked rhodanine?quinoline hybrids as upgraded antimicrobial agents

Chemical Biology and Drug Design

This review highlights the recent advances (2013–2023) in the pharmacology of rhodanine-linked quinoline hybrids as more effective antimicrobial agents. In the drug development process, linker hybrids acquire the top position due to their excellent π-stacking and Van der Waals interaction with the DNA active sites of pathogens.

DNA 100
article thumbnail

Women in Stem with Dr Emily Leproust

Drug Target Review

After some time in that role and launching several products, I received a call from Bill Banyai and Bill Peck, or ‘The Bills’ as we call them, who were building a company around technology that creates DNA by ‘writing’ it on a silicon chip. Twist was officially founded in 2013. At that time synesthetic biology wasn’t cool.

DNA 116
article thumbnail

The Biotech Startup Contraction Continues… And That’s A Good Thing

LifeSciVC

Beyond simply backing great science (separating the wheat from the chafe), setting a company up properly is critical, and early choices can get locked into the DNA of the company. Some continue to do so today, unfortunately, but there appears to be less of it happening. Second, great teams of truly experienced leaders are scarce.

DNA 112
article thumbnail

The power of combinations in blood cancers

Drug Target Review

At AstraZeneca and beyond we are exploring the use of cell-free DNA (cfDNA) methods to assess minimal residual disease as a possible intermediate endpoint across several disease types. 2013); 108(3): 479-485. Cancers (Basel). 2022;14(9):2182. Published 2022 Apr 27. doi:10.3390/cancers14092182 Fisher R, et al. Br J Cancer.